Core Viewpoint - Trinity Biotech plc has received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement for its American Depositary Shares (ADSs), which must be at least $1.00 per share for 30 consecutive business days [1][2]. Company Compliance Status - The notice does not immediately affect the trading status of the Company's ADSs, which will continue to be listed on the Nasdaq Global Select Market under the symbol "TRIB" [2]. - The Company has a 180-calendar day period, until August 10, 2026, to regain compliance with the minimum bid price requirement [2]. - To regain compliance, the closing bid price of the Company's ADSs must meet or exceed $1.00 for at least ten consecutive business days during this grace period [2]. Management's Response - The Company's management is actively monitoring the bid price of its ADSs and intends to cure the deficiency within the grace period [3]. - Various options are being evaluated by management to regain compliance and maintain the continued listing of the ADSs [3]. Company Overview - Trinity Biotech is a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors [5]. - The Company develops, acquires, manufactures, and markets diagnostic systems for point-of-care and clinical laboratory segments, and has recently entered the wearable biosensor industry through the acquisition of Waveform Technologies Inc. [5]. - Products include systems to detect infectious diseases and quantify Haemoglobin A1c levels, with sales occurring directly in the U.S. and through international distributors in over 75 countries [6].

Core Insights - Trinity Biotech has reached a critical profitability inflection point and expects to be Adjusted EBITDA positive and cash flow positive starting Q3 2025 [1][5][10] - The company has undergone significant operational restructuring to reduce costs and improve efficiency, laying the groundwork for sustainable profitability [5][10] - Trinity Biotech is focusing on growth opportunities, including the international rollout of new products and the development of innovative diagnostic solutions [5][12] Financial Performance - For Q1 2025, Trinity Biotech reported revenue of $7.6 million, with a gross profit of $1.9 million and an operating loss of $6.5 million [10] - The company anticipates a significant increase in revenue for Q2 2025, projecting a range of approximately $11 million to $12 million due to ramped-up manufacturing and normalized demand for rapid HIV tests [10] - The company expects further revenue growth in Q3 2025, driven by the resumption of manufacturing and supply of its flagship rapid HIV test, TrinScreen HIV [10] Strategic Developments - The company is advancing its next-generation continuous glucose monitoring (CGM) solution, which is seen as a major growth opportunity in the $13 billion global CGM market [5] - Trinity Biotech is also progressing towards commercialization of key medium-term growth drivers, including a preeclampsia screening test and a prostate cancer test [5] - The company has completed a pre-pivotal trial on its upgraded sensor technology for the CGM solution and plans to unveil key aspects of this innovative design soon [5]